B014: t细胞Elispot水平小组2017/2018:评估常规t细胞Elispot检测

S. Haley, Charlotte Halgreen, K. Frederiksen, R. Brogaard, L. Brix
{"title":"B014: t细胞Elispot水平小组2017/2018:评估常规t细胞Elispot检测","authors":"S. Haley, Charlotte Halgreen, K. Frederiksen, R. Brogaard, L. Brix","doi":"10.1158/2326-6074.CRICIMTEATIAACR18-B014","DOIUrl":null,"url":null,"abstract":"Monitoring antigen-specific T-cell responses is becoming increasingly important in Immunotherapeutic research and development. Thanks to the harmonization efforts by the CIC and CIMT over many years, and the development of better reagents and protocols, MHC multimer and T-cell Elispot assays are now more reliable and accurate assays for monitoring antigen-specific T-cell immunity. Supported by CIMT and CIC, Immudex has conducted a T-cell Elispot proficiency panel Winter 2017/2018 to evaluate assay performance in immune monitoring laboratories routinely doing T-cell Elispot assays. 39 worldwide participants received two cell samples, together representing low, medium and high responses for two predefined peptide pools. A negative control reagent was also included. Participants were asked to use the Direct Human IFNγ Elispot Assay to determine spot count corresponding to each of the predefined peptide pools and the negative control reagent. After performing the Direct Human IFNγ Elispot Assay, the participants report back their results for each cell sample as “number of spots per 200.000 viable cells” for each of the predefined peptide pools and negative control reagent. The data set was analyzed, and each participating laboratory received a report detailing the individual laboratory’s performance (in an anonymized format). The anonymized report was publicly available April 2018, and data will be presented at the CRI-CIMT-EATI-AACR Fourth International Cancer Immunotherapy Conference. Citation Format: Stephen T. Haley, Charlotte Halgreen, Katrine Frederiksen, Rikke Brogaard, Liselotte Brix. T-cell Elispot Proficiency Panel 2017/2018: Evaluating routine T-cell Elispot assays [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr B014.","PeriodicalId":352838,"journal":{"name":"Convergence of Technology and Cancer Immunotherapy","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract B014: T-cell Elispot Proficiency Panel 2017/2018: Evaluating routine T-cell Elispot assays\",\"authors\":\"S. Haley, Charlotte Halgreen, K. Frederiksen, R. Brogaard, L. Brix\",\"doi\":\"10.1158/2326-6074.CRICIMTEATIAACR18-B014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Monitoring antigen-specific T-cell responses is becoming increasingly important in Immunotherapeutic research and development. Thanks to the harmonization efforts by the CIC and CIMT over many years, and the development of better reagents and protocols, MHC multimer and T-cell Elispot assays are now more reliable and accurate assays for monitoring antigen-specific T-cell immunity. Supported by CIMT and CIC, Immudex has conducted a T-cell Elispot proficiency panel Winter 2017/2018 to evaluate assay performance in immune monitoring laboratories routinely doing T-cell Elispot assays. 39 worldwide participants received two cell samples, together representing low, medium and high responses for two predefined peptide pools. A negative control reagent was also included. Participants were asked to use the Direct Human IFNγ Elispot Assay to determine spot count corresponding to each of the predefined peptide pools and the negative control reagent. After performing the Direct Human IFNγ Elispot Assay, the participants report back their results for each cell sample as “number of spots per 200.000 viable cells” for each of the predefined peptide pools and negative control reagent. The data set was analyzed, and each participating laboratory received a report detailing the individual laboratory’s performance (in an anonymized format). The anonymized report was publicly available April 2018, and data will be presented at the CRI-CIMT-EATI-AACR Fourth International Cancer Immunotherapy Conference. Citation Format: Stephen T. Haley, Charlotte Halgreen, Katrine Frederiksen, Rikke Brogaard, Liselotte Brix. T-cell Elispot Proficiency Panel 2017/2018: Evaluating routine T-cell Elispot assays [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr B014.\",\"PeriodicalId\":352838,\"journal\":{\"name\":\"Convergence of Technology and Cancer Immunotherapy\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Convergence of Technology and Cancer Immunotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-B014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Convergence of Technology and Cancer Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-B014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

监测抗原特异性t细胞反应在免疫治疗研究和发展中变得越来越重要。由于CIC和CIMT多年来的协调努力,以及更好的试剂和方案的发展,MHC多聚体和t细胞Elispot检测现在是更可靠和准确的检测抗原特异性t细胞免疫的方法。在CIMT和CIC的支持下,Immudex在2017/2018冬季进行了t细胞Elispot熟练度测试,以评估常规进行t细胞Elispot检测的免疫监测实验室的检测性能。39名全球参与者收到了两个细胞样本,分别代表了两个预定义肽池的低、中、高反应。阴性对照试剂也包括在内。参与者被要求使用直接人IFNγ Elispot检测来确定每个预定义肽池和阴性对照试剂对应的斑点计数。在进行直接人IFNγ Elispot检测后,参与者报告每个细胞样本的结果,即每个预定义肽池和阴性对照试剂的“每200,000个活细胞的斑点数”。对数据集进行分析,每个参与的实验室都收到一份报告,详细说明了各自实验室的表现(以匿名格式)。该匿名报告于2018年4月公开发布,数据将在CRI-CIMT-EATI-AACR第四届国际癌症免疫治疗会议上公布。引文格式:Stephen T. Haley, Charlotte Halgreen, Katrine Frederiksen, Rikke Brogaard, Liselotte Brix。t细胞Elispot水平小组2017/2018:评估常规t细胞Elispot检测[摘要]。第四届CRI-CIMT-EATI-AACR国际癌症免疫治疗会议:将科学转化为生存;2018年9月30日至10月3日;纽约,纽约。费城(PA): AACR;癌症免疫学杂志,2019;7(2增刊):摘要nr B014。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Abstract B014: T-cell Elispot Proficiency Panel 2017/2018: Evaluating routine T-cell Elispot assays
Monitoring antigen-specific T-cell responses is becoming increasingly important in Immunotherapeutic research and development. Thanks to the harmonization efforts by the CIC and CIMT over many years, and the development of better reagents and protocols, MHC multimer and T-cell Elispot assays are now more reliable and accurate assays for monitoring antigen-specific T-cell immunity. Supported by CIMT and CIC, Immudex has conducted a T-cell Elispot proficiency panel Winter 2017/2018 to evaluate assay performance in immune monitoring laboratories routinely doing T-cell Elispot assays. 39 worldwide participants received two cell samples, together representing low, medium and high responses for two predefined peptide pools. A negative control reagent was also included. Participants were asked to use the Direct Human IFNγ Elispot Assay to determine spot count corresponding to each of the predefined peptide pools and the negative control reagent. After performing the Direct Human IFNγ Elispot Assay, the participants report back their results for each cell sample as “number of spots per 200.000 viable cells” for each of the predefined peptide pools and negative control reagent. The data set was analyzed, and each participating laboratory received a report detailing the individual laboratory’s performance (in an anonymized format). The anonymized report was publicly available April 2018, and data will be presented at the CRI-CIMT-EATI-AACR Fourth International Cancer Immunotherapy Conference. Citation Format: Stephen T. Haley, Charlotte Halgreen, Katrine Frederiksen, Rikke Brogaard, Liselotte Brix. T-cell Elispot Proficiency Panel 2017/2018: Evaluating routine T-cell Elispot assays [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr B014.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信